Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

R. S. Finn, M. Kudo, P. Merle, T. Meyer, S. Qin, M. Ikeda, R. Xu,J. Edeline,B-Y. Ryoo, Z. Ren,A-L. Cheng,P. R. Galle, S. Kaneko,H. Kumada, A. Wang,K. Mody, L. Dubrovsky, A. B. Siegel, J. Llovet

ANNALS OF ONCOLOGY（2022）

引用 95|浏览1

暂无评分

摘要

The global, randomized, double-blind, Ph3 LEAP-002 study (NCT03713593) evaluated the efficacy and safety of lenvatinib + pembrolizumab (lenva + pembro) vs lenvatinib (lenva) + placebo as 1L therapy for aHCC.

查看译文

关键词

advanced hepatocellular carcinoma,hepatocellular carcinoma,pembrolizumab,lenvatinib,first-line

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要